ANALYSIS OF THE USE OF USTEKINUMAB FOR CROHN DISEASE IN THE REAL CLINICAL PRACTICE

G. Miron Elorriaga, A. Iglesias Lambarri, A. Martin Torrente, O. Mora Atorrasagasti, M. Palacios Filardo, O. Ibarra Barrueta, L. Torio Alvarez, Y. Viseda Torrellas, I. Palacios Zabalza, L. Menendez Liendo, I. Ibarroondo Larramendi. Hospital Galdakao-Usansolo, Pharmacy, Galdakao, Spain

BACKGROUND AND IMPORTANCE

Ustekinumab (UST) is an anti-IL-12/23 antibody which is used in Crohn disease. Although the dosage form is defined in its data sheet, in the clinical practice, intensifications and intravenous reinductions are performed when there is a loss or inadequate of response.

OBJECTIVE

To describe and evaluate the different dosage regimens of UST performed in patients with Crohn disease by relating them to biomarkers of inflammation and clinical data.

MATERIAL AND METHODS

- Retrospective observational study
- Patient who started UST from January 2017 to April 2022

RESULTS

UST was effective in the majority of our cohort of patients. More than half of the patients required shortening of dosage interval and a fifth part of these also required one or two intravenous reinductions to control the disease.

CONCLUSIONS

United Kingdom